CHURCHILL MANAGEMENT Corp Boosts Position in Celgene Corporation (CELG)

CHURCHILL MANAGEMENT Corp increased its position in shares of Celgene Corporation (NASDAQ:CELG) by 9.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 45,117 shares of the biopharmaceutical company’s stock after buying an additional 3,921 shares during the quarter. CHURCHILL MANAGEMENT Corp’s holdings in Celgene Corporation were worth $5,859,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of CELG. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Celgene Corporation during the first quarter worth about $118,000. Oakworth Capital Inc. grew its holdings in shares of Celgene Corporation by 60.9% during the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 412 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in shares of Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 380 shares in the last quarter. Schmidt P J Investment Management Inc. bought a new position in shares of Celgene Corporation during the first quarter worth about $201,000. Finally, North Star Asset Management Inc. bought a new position in shares of Celgene Corporation during the first quarter worth about $201,000. Institutional investors and hedge funds own 79.33% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “CHURCHILL MANAGEMENT Corp Boosts Position in Celgene Corporation (CELG)” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://ledgergazette.com/2017/09/24/churchill-management-corp-boosts-position-in-celgene-corporation-celg.html.

Celgene Corporation (NASDAQ:CELG) traded up 0.08% during trading on Friday, reaching $143.89. The company’s stock had a trading volume of 3,549,466 shares. The company has a market cap of $112.57 billion, a price-to-earnings ratio of 44.56 and a beta of 1.89. The stock’s 50 day moving average is $135.45 and its 200 day moving average is $127.81. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $144.19.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. Celgene Corporation’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.44 earnings per share. On average, equities analysts expect that Celgene Corporation will post $7.32 EPS for the current fiscal year.

A number of research firms recently issued reports on CELG. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $175.00 price objective on shares of Celgene Corporation in a report on Wednesday, August 9th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective for the company in a report on Wednesday, August 16th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $150.00 price objective on shares of Celgene Corporation in a report on Friday, July 14th. Jefferies Group LLC reiterated a “buy” rating and set a $160.00 price objective on shares of Celgene Corporation in a report on Monday, July 31st. Finally, Robert W. Baird reiterated a “buy” rating and set a $162.00 price objective on shares of Celgene Corporation in a report on Thursday. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $149.34.

In other Celgene Corporation news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the sale, the director now owns 85,551 shares in the company, valued at $12,110,599.56. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ernest Mario sold 18,506 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the sale, the director now owns 69,424 shares in the company, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 63,006 shares of company stock worth $8,490,806. Company insiders own 0.95% of the company’s stock.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply